NVCT Relative Valuation
NVCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVCT is overvalued; if below, it's undervalued.
Historical Valuation
Nuvectis Pharma Inc (NVCT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.94. The fair price of Nuvectis Pharma Inc (NVCT) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.85
Fair
-7.36
PE
1Y
3Y
5Y
-5.76
EV/EBITDA
Nuvectis Pharma Inc. (NVCT) has a current EV/EBITDA of -5.76. The 5-year average EV/EBITDA is -6.03. The thresholds are as follows: Strongly Undervalued below -10.32, Undervalued between -10.32 and -8.18, Fairly Valued between -3.88 and -8.18, Overvalued between -3.88 and -1.73, and Strongly Overvalued above -1.73. The current Forward EV/EBITDA of -5.76 falls within the Historic Trend Line -Fairly Valued range.
-6.19
EV/EBIT
Nuvectis Pharma Inc. (NVCT) has a current EV/EBIT of -6.19. The 5-year average EV/EBIT is -6.37. The thresholds are as follows: Strongly Undervalued below -11.22, Undervalued between -11.22 and -8.79, Fairly Valued between -3.95 and -8.79, Overvalued between -3.95 and -1.53, and Strongly Overvalued above -1.53. The current Forward EV/EBIT of -6.19 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Nuvectis Pharma Inc. (NVCT) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Nuvectis Pharma Inc. (NVCT) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.82. The thresholds are as follows: Strongly Undervalued below -17.96, Undervalued between -17.96 and -11.89, Fairly Valued between 0.25 and -11.89, Overvalued between 0.25 and 6.33, and Strongly Overvalued above 6.33. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Nuvectis Pharma Inc. (NVCT) has a current P/FCF of 0.00. The 5-year average P/FCF is -4.84. The thresholds are as follows: Strongly Undervalued below -14.88, Undervalued between -14.88 and -9.86, Fairly Valued between 0.17 and -9.86, Overvalued between 0.17 and 5.19, and Strongly Overvalued above 5.19. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Nuvectis Pharma Inc (NVCT) has a current Price-to-Book (P/B) ratio of 9.09. Compared to its 3-year average P/B ratio of 11.32 , the current P/B ratio is approximately -19.71% higher. Relative to its 5-year average P/B ratio of 10.26, the current P/B ratio is about -11.45% higher. Nuvectis Pharma Inc (NVCT) has a Forward Free Cash Flow (FCF) yield of approximately -6.65%. Compared to its 3-year average FCF yield of -9.19%, the current FCF yield is approximately -27.62% lower. Relative to its 5-year average FCF yield of -9.30% , the current FCF yield is about -28.48% lower.
9.09
P/B
Median3y
11.32
Median5y
10.26
-6.65
FCF Yield
Median3y
-9.19
Median5y
-9.30
Competitors Valuation Multiple
The average P/S ratio for NVCT's competitors is 3.07, providing a benchmark for relative valuation. Nuvectis Pharma Inc Corp (NVCT) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NVCT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NVCT in the past 1 year is driven by Unknown.
People Also Watch
UPLD
Upland Software Inc
1.49USD
-0.67%
VRA
Vera Bradley Inc
3.15USD
-1.56%
TAYD
Taylor Devices Inc
68.12USD
1.04%
SND
Smart Sand Inc
3.84USD
-0.52%
TELA
TELA Bio Inc
1.09USD
-2.68%
SOL
Emeren Group Ltd
1.94USD
0.52%
BRAG
Bragg Gaming Group Inc
2.23USD
2.53%
PETS
Petmed Express Inc
3.32USD
-1.48%
MIST
Milestone Pharmaceuticals Inc
2.19USD
1.86%
Frequently Asked Questions
Is Nuvectis Pharma Inc (NVCT) currently overvalued or undervalued?
Nuvectis Pharma Inc (NVCT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.94. The fair price of Nuvectis Pharma Inc (NVCT) is between to according to relative valuation methord.
What is Nuvectis Pharma Inc (NVCT) fair value?
NVCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nuvectis Pharma Inc (NVCT) is between to according to relative valuation methord.
How does NVCT's valuation metrics compare to the industry average?
The average P/S ratio for NVCT's competitors is 3.07, providing a benchmark for relative valuation. Nuvectis Pharma Inc Corp (NVCT) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Nuvectis Pharma Inc (NVCT) as of Jan 08 2026?
As of Jan 08 2026, Nuvectis Pharma Inc (NVCT) has a P/B ratio of 9.09. This indicates that the market values NVCT at 9.09 times its book value.
What is the current FCF Yield for Nuvectis Pharma Inc (NVCT) as of Jan 08 2026?
As of Jan 08 2026, Nuvectis Pharma Inc (NVCT) has a FCF Yield of -6.65%. This means that for every dollar of Nuvectis Pharma Inc’s market capitalization, the company generates -6.65 cents in free cash flow.
What is the current Forward P/E ratio for Nuvectis Pharma Inc (NVCT) as of Jan 08 2026?
As of Jan 08 2026, Nuvectis Pharma Inc (NVCT) has a Forward P/E ratio of -7.36. This means the market is willing to pay $-7.36 for every dollar of Nuvectis Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nuvectis Pharma Inc (NVCT) as of Jan 08 2026?
As of Jan 08 2026, Nuvectis Pharma Inc (NVCT) has a Forward P/S ratio of 0.00. This means the market is valuing NVCT at $0.00 for every dollar of expected revenue over the next 12 months.